Prinomastat (BioDeep_00000778812)

   


代谢物信息卡片


Prinomastat

化学式: C18H21N3O5S2 (423.09225760000004)
中文名称: 普马司他
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1(C(N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OC3=CC=NC=C3)C(=O)NO)C
InChI: InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1

描述信息

D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D061965 - Matrix Metalloproteinase Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C1970 - Matrix Metalloproteinase Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor

同义名列表

1 个代谢物同义名

Prinomastat



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Abhinandan Chowdhury, Christina N Zdenek, James S Dobson, Lachlan A Bourke, Raul Soria, Bryan G Fry. Clinical implications of differential procoagulant toxicity of the palearctic viperid genus Macrovipera, and the relative neutralization efficacy of antivenoms and enzyme inhibitors. Toxicology letters. 2021 Apr; 340(?):77-88. doi: 10.1016/j.toxlet.2020.12.019. [PMID: 33412251]
  • Yasuto Kido, Pär Matsson, Kathleen M Giacomini. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011 Jul; 54(13):4548-58. doi: 10.1021/jm2001629. [PMID: 21599003]
  • Marion Flipo, Julie Charton, Akila Hocine, Sandrine Dassonneville, Benoit Deprez, Rebecca Deprez-Poulain. Hydroxamates: relationships between structure and plasma stability. Journal of medicinal chemistry. 2009 Nov; 52(21):6790-802. doi: 10.1021/jm900648x. [PMID: 19821586]
  • Georgina S Butler, Richard A Dean, Eric M Tam, Christopher M Overall. Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding. Molecular and cellular biology. 2008 Aug; 28(15):4896-914. doi: 10.1128/mcb.01775-07. [PMID: 18505826]
  • G S Butler, C M Overall. Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry. Current pharmaceutical design. 2007; 13(3):263-70. doi: 10.2174/138161207779313524. [PMID: 17313360]
  • Kenneth R Hande, Mary Collier, Linda Paradiso, Jill Stuart-Smith, Mary Dixon, Neil Clendeninn, Geoff Yeun, Donna Alberti, Kim Binger, George Wilding. Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Feb; 10(3):909-15. doi: 10.1158/1078-0432.ccr-0981-3. [PMID: 14871966]
  • Jiang Liu, Ming S Tsao, Marco Pagura, David R Shalinsky, Rama Khoka, Jim Fata, Michael R Johnston. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Lung cancer (Amsterdam, Netherlands). 2003 Dec; 42(3):335-44. doi: 10.1016/s0169-5002(03)00355-6. [PMID: 14644522]
  • D R Shalinsky, J Brekken, H Zou, L A Bloom, C D McDermott, S Zook, N M Varki, K Appelt. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Jul; 5(7):1905-17. doi: NULL. [PMID: 10430098]
  • A Price, Q Shi, D Morris, M E Wilcox, P M Brasher, N B Rewcastle, D Shalinsky, H Zou, K Appelt, R N Johnston, V W Yong, D Edwards, P Forsyth. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Apr; 5(4):845-54. doi: NULL. [PMID: 10213221]
  • D R Shalinsky, J Brekken, H Zou, S Kolis, A Wood, S Webber, K Appelt. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Investigational new drugs. 1998 199; 16(4):303-13. doi: 10.1023/a:1006204901140. [PMID: 10426662]